Association between ABCB1 Polymorphisms and Antidepressant Treatment Response in Taiwanese Major Depressive Patients
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: The multidrug resistance 1 (ABCB1, MDR1) gene, encoding P-glycoprotein, is extensively distributed and expressed in various tissues, such as a blood-brain barrier transporter. P-glycoprotein plays an important role in controlling the passage of substances between the blood and brain. The current study aimed to investigate possible associations of functional ABCB1 polymorphisms (C3435T, G2677T and C1236T) with response to antidepressant treatment and serum cortisol levels in Taiwanese patients with major depressive disorder (MDD). Methods: We recruited 112 MDD patients who were randomized to fluoxetine (n=58, mean dose: 21.4±4.5 mg/day) or venlafaxine (n=54, 80.2±34.7 mg/day) treatment for 6 weeks. The 21-item Hamilton Depression Rating Scale (HDRS) was administered initially and biweekly after treatment, and cortisol levels were assessed initially and after 6-week antidepressant treatment. Results: The initial HDRS scores and the HDRS scores after six weeks of antidepressant treatment were not significantly different among the different genotypes in each polymorphism of ABCB1. The percentage changes of HDRS scores over time were significantly different in the polymorphisms of ABCB1 G2677T (p=0.002). MDD patients with the G/G genotype of ABCB1 G2677T had a worse antidepressant treatment response. However, the polymorphisms of ABCB1 genotypes were not significantly associated with cortisol levels before and after antidepressant treatment in MDD patients. Conclusion: The results suggested that the variants of ABCB1 may influence the short-term antidepressant response in MDD patients. Further details of the underlying mechanisms of ABCB1 in antidepressant treatment remain to be clarified.
Abstract
Objective: The multidrug resistance 1 (ABCB1, MDR1) gene, encoding P-glycoprotein, is extensively distributed and expressed in various tissues, such as a blood-brain barrier transporter. P-glycoprotein plays an important role in controlling the passage of substances between the blood and brain. The current study aimed to investigate possible associations of functional ABCB1 polymorphisms (C3435T, G2677T and C1236T) with response to antidepressant treatment and serum cortisol levels in Taiwanese patients with major depressive disorder (MDD). Methods: We recruited 112 MDD patients who were randomized to fluoxetine (n=58, mean dose: 21.4±4.5 mg/day) or venlafaxine (n=54, 80.2±34.7 mg/day) treatment for 6 weeks. The 21-item Hamilton Depression Rating Scale (HDRS) was administered initially and biweekly after treatment, and cortisol levels were assessed initially and after 6-week antidepressant treatment. Results: The initial HDRS scores and the HDRS scores after six weeks of antidepressant treatment were not significantly different among the different genotypes in each polymorphism of ABCB1. The percentage changes of HDRS scores over time were significantly different in the polymorphisms of ABCB1 G2677T (p=0.002). MDD patients with the G/G genotype of ABCB1 G2677T had a worse antidepressant treatment response. However, the polymorphisms of ABCB1 genotypes were not significantly associated with cortisol levels before and after antidepressant treatment in MDD patients. Conclusion: The results suggested that the variants of ABCB1 may influence the short-term antidepressant response in MDD patients. Further details of the underlying mechanisms of ABCB1 in antidepressant treatment remain to be clarified.
참고문헌 (28)
- Schinkel AH., "P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs", J Clin Invest, 97, pp.2517~2524 (1996)
- Singh AB., "ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression", Transl Psychiatry, 2, pp.e198~ (2012)
- Ueda K., "The human multidrug resistance(mdr1)gene. cDNA cloning and transcription initiation", J Biol Chem, 262, pp.505~508 (1987)
- Jaquenoud Sirot E., "ABCB1 and cytochrome P450 polymorphisms : clinical pharmacogenetics of clozapine", J Clin Psychopharmacol, 29, pp.319~326 (2009)
- Uhr M., "Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression", Neuron, 57, pp.203~209 (2008)
- O'Brien FE., "Interactions between antidepressants and P-glycoprotein at the blood-brain barrier : clinical significance of in vitro and in vivo findings", Br J Pharmacol, 165, pp.289~312 (2012)
- Sakaeda T., "MDR1 genotype-related pharmacokinetics and pharmacodynamics", Biol Pharm Bull, 25, pp.1391~1400 (2002)
- Uhr M., "Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to Mdr1a P-glycoprotein gene disruption", Neuropsychopharmacology, 22, pp.380~387 (2000)
- Weiss J., "Inhibition of P-glycoprotein by newer antidepressants", J Pharmacol Exp Ther, 305, pp.197~204 (2003)
- Fujii T., "Association between the functional polymorphism(C3435T)of the gene encoding P-glycoprotein(ABCB1)and major depressive disorder in the Japanese population", J Psychiatr Res, 46, pp.555~559 (2012)
- Lin KM., "ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment", Pharmacogenet Genomics, 21, pp.163~170 (2011)
- Nakamura T., "Effects of ABCB1 3435C>T genotype on serum levels of cortisol and aldosterone in women with normal menstrual cycles", Genet Mol Res, 8, pp.397~403 (2009)
- Yau JL., "The antidepressant desipramine requires the ABCB1(Mdr1)-type p-glycoprotein to upregulate the glucocorticoid receptor in mice", Neuropsychopharmacology, 32, pp.2520~2529 (2007)
- Sheehan DV., "The Mini-International Neuropsychiatric Interview(M. I. N. I. ) : the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry", 59 Suppl, 20, pp.22~33 (1998)
- Redrobe JP., "Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity", Psychopharmacology(Berl), 138, pp.1~8 (1998)
- Bochud M., "Association of ABCB1 genetic variants with renal function in Africans and in Caucasians", BMC Med Genomics, 1, pp.21~ (2008)
- Ishikawa T., "Emerging new technologies in Pharmacogenomics : rapid SNP detection, molecular dynamic simulation, and QSAR analysis methods to validate clinically important genetic variants of human ABC Transporter ABCB1(P-gp", MDR1), 2010, pp.126, 69~81
- Thiebaut F., "Cellular localization of the multidrugresistance gene product P-glycoprotein in normal human tissues", Proc Natl Acad Sci U S A, 84, pp.7735~7738 (1987)
- Ferner RE., "ABCB1(P-glycoprotein)and the clinical pharmacology of adverse drug reactions", Adverse Drug Reaction Bulletin, 2010, pp.1011~1014 (2010)
- Kim RB., "Identification of functionally variant MDR1 alleles among European Americans and African Americans", Clin Pharmacol Ther, 70, pp.189~199 (2001)
- Owen A., "Relationship between the C3435T and G2677T(A)polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver", Br J Clin Pharmacol, 59, pp.365~370 (2005)
- Tanabe M., "Expression of P-glycoprotein in human placenta : relation to genetic polymorphism of the multidrug resistance(MDR)-1 gene", J Pharmacol Exp Ther, 297, pp.1137~1143 (2001)
- Sarginson JE., "ABCB1(MDR1)polymorphisms and antidepressant response in geriatric depression", Pharmacogenet Genomics, 20, pp.467~475 (2010)
- Kato M., "ABCB1(MDR1)gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder", Prog Neuropsychopharmacol Biol Psychiatry, 32, pp.398~404 (2008)
- Nikisch G., "Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response : a pilot study", Pharmacol Res, 58, pp.344~347 (2008)
- Müller MB., "ABCB1(MDR1)-type P-glycoproteins at the blood-brain barrier modulate the activity of the hypothalamic-pituitary-adrenocortical system : implications for affective disorder", Neuropsychopharmacology, 28, pp.1991~1999 (2003)
- Pariante CM., "Do antidepressants regulate how cortisol affects the brain?", Psychoneuroendocrinology, 29, pp.423~447 (2004)
- Pariante CM., "The HPA axis in major depression : classical theories and new developments", Trends Neurosci, 31, pp.464~468 (2008)